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Abstract 32 
Background: Lockdown measures have been enforced globally in response to the COVID-19 33 
pandemic. Given the comorbidity burden in women with polycystic ovary syndrome (PCOS), these 34 
lockdown measures may have a particularly negative impact on sleep health, quality of life (QoL), and 35 
depression/stress levels in this population. The aim of this study was to explore whether such potential 36 
problems were present in women with PCOS during the COVID-19 lockdown in the UK.  37 
Methods: UK women with PCOS were recruited through social media into a cross-sectional study 38 
during the COVID-19 lockdown. The study survey was delivered online, and included demographic 39 
and COVID-19 relevant questions, as well as validated questionnaires/scales, namely the Insomnia 40 
Severity Index (ISI), Depression Anxiety and Stress Scale (DASS-21), and PCOSQOL questionnaire.  41 
Results: 333 women with PCOS [median age: 30.0 (9.0) years] were recruited. Participants were 42 
dichotomized based on responses regarding the impact of COVID-19 restrictions on their sleep 43 
[negative (N=242) versus no/positive (N=91) impact]. No differences were noted between groups 44 
regarding age, time since PCOS diagnosis, body mass index, or number of comorbidities. Based on the 45 
ISI, 44.2% of participants reporting a negative impact on sleep exhibited at least moderately severe 46 
clinical insomnia. Compared to those who reported no/positive effect on sleep, the participants 47 
reporting a negative impact on sleep also reported poorer QoL, based on the total PCOSQOL score, 48 
with a greater impact of PCOS and poorer mood in the corresponding PCOSQOL domains. Based on 49 
the DASS-21, the latter also had statistically higher depression and stress levels compared to the 50 
former. Finally, for this cohort significant inverse correlations were noted between the ISI and 51 
PCOSQOL scores (total and domain scores), whilst the DASS-21 and ISI scores were positively 52 
correlated (all p-values <.001).   53 
Conclusion: The majority of recruited UK women with PCOS reported that the COVID-19 lockdown 54 
had a negative impact on their sleep, which was also associated with impaired QoL and higher 55 
depression/stress levels. Whilst further research is required, women with PCOS should be considered 56 
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a vulnerable population that may experience an adverse impact on sleep, QoL and mental health 57 
wellbeing due to lockdown measures during the COVID-19 pandemic. 58 
 59 
Keywords: Polycystic ovary syndrome (PCOS), COVID-19, lockdown, sleep, anxiety, depression, 60 
stress, quality of life 61 
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1 Introduction 63 
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-64 
2 (SARS-CoV-2), usually manifests as a respiratory tract infection with mild symptomatology 65 
(asymptomatic in many cases) (1-3). However, COVID-19 can also lead to severe manifestations in a 66 
proportion of high-risk individuals with respiratory and/or extra-pulmonary symptoms/complications 67 
requiring hospitalization (1-3). As the latter may require intensive care unit (ICU) support and may 68 
even be fatal, the COVID-19 pandemic has resulted in enforcement of varying degrees of nationwide 69 
lockdown, quarantine and self-isolation measures in many countries worldwide (4, 5). These measures 70 
aim to reduce SARS-CoV-2 transmission in the general population, and thus the risk of severe COVID-71 
19 in vulnerable groups (e.g., older individuals and patients with certain respiratory and cardio-72 
metabolic diseases) (6-12). Indeed, compelling evidence strongly indicates that certain chronic cardio-73 
metabolic diseases, including diabetes and obesity, constitute key risk factors predisposing to severe 74 
COVID-19 (6-12). Notably, although severe COVID-19 is more common in men (13, 14), the 75 
aforementioned cardio-metabolic comorbidities, which significantly increase the risk of adverse 76 
COVID-19 related clinical outcomes, are also markedly prevalent in women with polycystic ovary 77 
syndrome (PCOS) (15-17). 78 
PCOS is the most common endocrine disorder in reproductive-aged women, affecting up to 15-20% 79 
of this female population depending on the studied population and the applied diagnostic definition 80 
(18, 19). After excluding other endocrinopathies with similar symptomatology (19, 20), PCOS is 81 
typically diagnosed based on the presence of at least two out of three diagnostic criteria, namely 82 
ovulatory dysfunction, hyperandrogenism (clinical and/or biochemical) and polycystic ovaries (PCO) 83 
as identified by ultrasound (21). In addition, women with PCOS are also at a high risk of cardio-84 
metabolic complications, particularly obesity, insulin resistance, type 2 diabetes (T2DM), 85 
hypertension, non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnoea (OSA) (22-27). 86 
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Furthermore, women with PCOS often exhibit psychological comorbidity, with higher prevalence of 87 
coexisting anxiety and/or depression (28-31), which also tends to impair their overall quality of life 88 
(QoL) compared to women without PCOS (32, 33). Given this increased comorbidity burden, women 89 
with PCOS may experience a particularly negative impact from the lockdown/quarantine and self-90 
isolation measures imposed against the transmission of SARS-CoV-2 and may also be at increased risk 91 
of severe COVID-19 (16).  92 
Overall, global measures to control the COVID-19 pandemic are expected to inevitably have a negative 93 
psychological effect upon the general population (34) due to various factors, including the enforced 94 
quarantine measures (35) and their socio-economic impact (36), as well as the concern about COVID-95 
19 (34). This has been previously reported in relation to SARS, which was shown to promote increased 96 
stress, anxiety and depression in the general population (37). Such findings are increasingly reported 97 
during the current COVID-19 pandemic, with an observed increase in self-reported symptoms of 98 
anxiety, depression and stress (38). Moreover, these negative psychological effects are likely linked to 99 
disrupted sleep quality (39). In previous longitudinal studies, new onset mental health issues have been 100 
linked to increased sleep disruption (40-42), whilst disturbed sleep is also considered to be a 101 
contributing factor to the development of new mental health disorders (43). Of note, irrespective of the 102 
COVID-19 pandemic, sleep disturbances are more prevalent in women with PCOS than in the general 103 
population (44, 45), potentially due to coexisting OSA, particularly in women with poorer metabolic 104 
profiles (26), and/or depression which is also a major predictor of poor sleep quality (46). Furthermore, 105 
reduced self-esteem and body satisfaction, which are both frequently associated with PCOS, have also 106 
been demonstrated to contribute towards disrupted sleep (44).  107 
In this context, it is likely that a two-fold effect of increased psychological distress due to the COVID-108 
19 pandemic alongside the established disease-related burden of PCOS may further contribute to 109 
impaired sleep quality and QoL, linked also to increased anxiety, depression and stress levels (47). To 110 
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date, there have been no published studies exploring these issues in women with PCOS during the 111 
COVID-19 pandemic. Therefore, the aim of the current study was to determine whether the COVID-112 
19 pandemic has had a negative effect upon the sleep quality of women with PCOS in the United 113 
Kingdom (UK), and whether any such impairment was associated with reduced QoL and increased 114 
stress, anxiety or depression in this female population.  115 
2 Methods 116 
For the purposes of this study, we conducted a cross-sectional study based on a web-based survey 117 
between 2nd June and 17th August 2020. Ethical approval was granted by the ethics committee of 118 
Coventry University (application number: P106195) in May 2020. Recruitment was conducted through 119 
social media and with the support of Verity (the UK PCOS charity) and PCOS support groups on 120 
Facebook. Participant eligibility criteria included female sex with a previous medical diagnosis of 121 
PCOS, age from 18 to 45 years, and UK residency. 122 
A range of structured and validated questionnaires were used to collect the study data; questionnaires 123 
were completed online using the survey software, Qualtrics© XM (Qualtrics XM, Provo, Utah, USA). 124 
Where participants expressed an interest in participation, a study URL link to the survey was emailed 125 
to them directly. Alternatively, participants could access the questionnaires directly via the same study 126 
URL posted on social media channels. The study URL link contained an initial participant information 127 
sheet, as well as provision of informed consent. Where participants failed to complete the provided 128 
online survey, this was translated as withdrawal from the study and all data for these participants were 129 
excluded from the final analyses. 130 
To capture relevant participant characteristics, a demographics questionnaire was created for this 131 
survey. This included self-reported information about time since PCOS diagnosis and diagnosed PCOS 132 
phenotype, height, weight, age, questions relating to sleep affected by COVID-19 restrictions (i.e. ‘to 133 
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what extent do you believe that quarantine measures due to COVID-19 have affected your sleep 134 
pattern?’), presence of comorbidities and typical sociodemographic questions. In the context of this 135 
study, the PCOSQOL was utilized as a validated measure of QoL (48). The PCOSQOL is a disease-136 
specific questionnaire which was developed and validated to measure QoL in UK women with PCOS, 137 
and is also the first PCOS-specific measurement tool to encompass all phenotypic subgroups according 138 
to the most recent diagnostic criteria (48). Briefly, this questionnaire incorporates 35 Likert-based 139 
questions allowing participants to report the impact of various PCOS-related symptoms upon their day-140 
to-day life, with subscales which allow reporting of the impact of PCOS, infertility, hirsutism and mood 141 
upon QoL (49-51). Total scores are summated with lower scores indicative of poorer QoL.  142 
Information about the mental health wellbeing of each participant was also captured using the 143 
Depression, Anxiety and Stress Scale (DASS-21) (52). The DASS-21 includes 21 questions, seven 144 
relating to each domain for depression, anxiety and stress, and requires respondents to rate their level 145 
of agreement (0-3) to a series of statements. Each domain score is calculated by summing the responses 146 
and multiplying by two, whilst normative and cut-points for depression, anxiety and stress are 147 
provided. Finally, the Insomnia Severity Index (ISI) was applied to measure participants’ self-148 
perceived insomnia (53), as a validated and reliable tool for the assessment of insomnia severity (54, 149 
55). The ISI targets the subjective symptoms and consequences of insomnia, as well as the degree of 150 
concerns or distress caused by those difficulties. The ISI is composed of seven items that, respectively, 151 
evaluate the severity of sleep-onset (initial), sleep maintenance (middle), early morning awakening 152 
problems (terminal), satisfaction with current sleep pattern, interference with daily functioning, 153 
noticeability of impairment attributed to the sleep problem, and level of distress caused by the sleep 154 
problem. Each of these items is rated on a five-point Likert scale and the time interval is “in the last 2 155 
weeks”. Total ISI scores range from 0-28, with higher scores indicating greater insomnia severity.  156 
Statistical Analysis 157 
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Statistical analysis was completed in IBM SPSS Statistics for Windows (Version 26.0, IBM Corp; 158 
Armonk, NY) and in R statistical software (R Core Team (2018). R: A Language and environment for 159 
statistical computing. [Computer software]. Retrieved from https://cran.r-project.org/), using the car: 160 
and MASS: packages) (56, 57), and statistical significance was set at p<0.05. Descriptive characteristic 161 
reports were generated and Shapiro-Wilk tests of normality were completed. Accordingly, a non-162 
parametric approach was adopted for subsequent analysis, as appropriate. Responses to the question 163 
‘to what extent do you believe that quarantine measures due to COVID-19 have affected your sleep 164 
pattern?’ were split into a dichotomous response – namely, into negative effects or no effect/positive 165 
effects – which was used as a categorical variable. Independent samples Mann-Whitney U tests were 166 
completed to evaluate the between group differences. Spearman’s correlations between the ISI and 167 
other questionnaires (i.e. PCOSQOL total and domain scores, and the DASS-21) were also completed 168 
for the entire study cohort and also within each group.  169 
Given the Likert scale nature of the data in this study, where Likert scales are a special case of ordinal 170 
data, we utilized an ordinal logistic regression (OLR) approach. The OLR approach is comparable to 171 
a conventional multiple regression approach, where there may be one dependent variable and one or 172 
more independent variables. It does however differ from ordinary least squares multiple regression, by 173 
treating the dependent variable as an ordered categorical variable, based upon the principle of 174 
cumulative-odds (58). The coefficient of determination, R2, summarizes the proportion of variance in 175 
the dependent variable associated with the independent variables, with larger R2 values indicating that 176 
more of the variation is explained by the model, to a maximum of 1. However, in non-parametric 177 
regression, it is not possible to compute a traditional R2, and a pseudo R2 is computed instead. In this 178 
study, we opted to report Nagelkerke’s R2 (R²N), which is an adjusted version of the Cox & Snell R
2 179 
that adjusts the scale of the statistic to cover the full range from 0 to 1 (59, 60). To test the statistical 180 
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significance of each model coefficient (β), we used the Wald test to compute a Wald statistic with a 181 
chi-square distribution. All participant background characteristics were adjusted for in the OLR.  182 
 183 
3 Results 184 
In total, 333 participants met the eligibility criteria and consented to participate in the present study, 185 
completing the online survey. Pertinent demographics/characteristics for the recruited study cohort are 186 
presented in Table 1. The vast majority of the study participants (92.5%) were of White ethnic 187 
background. Of the recruited cohort, 40% were married and a further 40% were single, with the 188 
remaining 20% being in other non-married relationships, divorced, separated or widowed. 189 
Approximately 73% of participants stated that they have no children. Moreover, the majority (63.1%) 190 
of the study participants were in full-time employment, 40.2% were educated to at least degree level, 191 
and 51.1% had the lowest household income (≤ £39,999). Finally, participants were asked to self-report 192 
their diagnosed PCOS phenotype; 46.5% indicated that they had all three PCOS diagnostic 193 
characteristics (i.e. hyperandrogenism, menstrual disruption, and PCO), 13.5% PCO and menstrual 194 
disruption, 9.6% PCO and hyperandrogenism, 6.9% hyperandrogenism and menstrual disruption, and 195 
the remaining 23.1% were unsure of the PCOS phenotype with which they had been diagnosed. 196 
***Insert Table 1 here*** 197 
When participants’ responses to the question about the impact of COVID-19 restrictions on their sleep 198 
were dichotomized into negative and no/positive responses, 242 participants reported that they had 199 
experienced either a significant or small negative effect upon their sleep, whilst the remaining 91 200 
reported either no such effect, or at least a small positive effect upon their sleep. Using the ISI scoring 201 
guidelines, 44.2% of those reporting negative effects met the scoring threshold (>14) for a diagnosis 202 
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of at least moderately severe clinical insomnia. Key outcomes of interest were compared between these 203 
two study groups and these findings are summarized in Table 2.  204 
***Insert Table 2 here*** 205 
Overall, there were no differences between the study groups regarding age, weight, body mass index 206 
(BMI), time since PCOS diagnosis, or number of comorbidities. As expected, the self-reported 207 
insomnia severity assessed by the ISI was significantly higher in those who reported a negative effect 208 
of COVID-19 on their sleep quality compared to those who reported no such effect or a relevant 209 
positive effect (Table 2). Furthermore, the former also reported poorer QoL, as measured by the total 210 
PCOSQOL score, whilst they also reported a greater impact of PCOS and poorer mood in the 211 
corresponding PCOSQOL domains. Finally, based on the corresponding DASS-21 scale scores, those 212 
reporting a negative effect of COVID-19 on their sleep quality also had statistically higher depression 213 
and stress levels, but not anxiety, compared to those who reported no such effect (Table 2).  214 
For the entire study cohort, Spearman’s correlation tests showed an inverse correlation between the ISI 215 
and PCOSQOL total score (rs = -.384, p <.001), and domain scores for Impact of PCOS (rs = -.379, p 216 
<.001), Infertility (rs = -.225, p <.001), Hirsutism (rs = -.205, p <.001), and Mood (rs = -.405, p <.001). 217 
Furthermore, significant positive correlations were also noted between the ISI and the DASS-21 218 
Depression (rs = .377, p <.001), Anxiety (rs = .410, p <.001), and Stress (rs = .467, p <.001) scores. 219 
These correlations between the ISI and the total PCOSQOL score, all PCOSQOL domains apart from 220 
Hirsutism, and DASS-21 scores also remained statistically significant within each of the two groups 221 
(data not shown).   222 
Results of the OLR indicated that Stress, Anxiety, and Depression, as measured by the DASS-21, 223 
alongside PCOSQOL domain scores for Mood, Hirsutism, Infertility, and Impact of PCOS were 224 
significant predictors of ISI score (all p values <.01; Table 3). Furthermore, we found that the DASS-225 
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21 variables were the greatest predictors of ISI score, accounting for the largest proportion of variance 226 
in the dependent variable (Stress: Wald χ²: 87.23, OR: 1.23 (1.18, 1.29), R²N: 0.05, p <.001; Anxiety: 227 
Wald χ²: 64.06, OR: 1.19 (1.14, 1.25), R²N: 0.03, p <.001; Depression: Wald χ²: 55.5, OR: 1.15 (1.11, 228 
1.20), R²N: 0.03, p <.001). Finally, no participant characteristic significantly influenced the direction 229 
or magnitude of the OLR (all p values >.2). 230 
***Insert Table 3 here*** 231 
4 Discussion 232 
To our knowledge, this is the first study to assess the self-reported sleep quality of women with PCOS 233 
in the UK during the lockdown/quarantine measures imposed in response to the COVID-19 pandemic, 234 
and explore potential corresponding associations with QoL and depression, anxiety, and stress levels 235 
in this female population. Of note, according to the findings of the present study approximately 73% 236 
of the study participants reported that their sleep quality had worsened since COVID-19 restrictions 237 
were imposed. Interestingly, when compared to data from a study in the general population during 238 
COVID-19 lockdown measures (61), the prevalence of clinical insomnia based upon the ISI among the 239 
women with PCOS of the present study was markedly greater (~35% vs ~10%). Our findings are in 240 
accord with data reported from a web-based study in the Greek general population during the national 241 
lockdown due to COVID-19, where 37.6% of participants (particularly women) scored above the 242 
threshold for insomnia based on a relevant validated questionnaire (62). Prior to the COVID-19 243 
pandemic, global estimates for the prevalence of insomnia ranged between 3.9% to 22% (63), thus 244 
these findings suggest that there has been an exacerbation of sleep disturbances (e.g., insomnia) during 245 
this pandemic.  246 
The present findings showing that the majority of women with PCOS self-report negative effects upon 247 
their sleep during the COVID-19 restrictions highlight insomnia and poor sleep health as a significant 248 
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problem in this female population. However, it should be noted that it is difficult to determine the 249 
magnitude of this problem/change without having relevant baseline assessments before this pandemic. 250 
Indeed, due to practical difficulties in studying women with PCOS in representative population-based 251 
samples, there is an overall paucity of data on the prevalence of sleep disturbances in this population 252 
to allow precise comparisons (64). Notably, one common known sleep disorder in women with PCOS 253 
is OSA, with a recent meta-analysis reporting that OSA prevalence in women with PCOS is 35% (95% 254 
confidence interval: 22.2 to 48.9%) which is further increased in the presence of overweight/obesity 255 
(45). Nevertheless, OSA does not appear to be a defining factor for the findings of the present study, 256 
since only 1.2% of participants indicated that they had received a medical diagnosis of OSA, and there 257 
were no between group differences for BMI or additional comorbidities (e.g., T2DM) that are often 258 
associated with PCOS and OSA (26). Undiagnosed OSA is common in this female population (26), 259 
and may also be present among the participants of this cohort, but whether this could be an underlying 260 
factor contributing to the present findings requires further and more targeted research.   261 
Another mechanism contributing to sleep disturbances in this study may relate to increased depression, 262 
anxiety and stress levels. Indeed, depression, anxiety and stress yield the largest beta coefficients and 263 
account for the largest amount of variance to ISI scores in the results of the ordinal logistic regression 264 
in the present study. Of interest, when the whole study cohort was considered, 51.5% reported that they 265 
had previously received a medical diagnosis of anxiety and/or stress. Whilst it was unclear whether 266 
these diagnoses were made prior to, or during the COVID-19 pandemic, additional insight can be 267 
gained from the self-reported DASS-21 scores. Based on this validated questionnaire, the prevalence 268 
rates of at least mild depression, anxiety, and stress in the study cohort were 80.5%, 70.6% and 64.6%, 269 
respectively, which are higher than the reported corresponding medical diagnoses. Notably, these are 270 
also higher than those reported by a meta-analysis for depression (33.7%; 95% CI: 27.5 to 40.6), 271 
anxiety (31.9%; 95% CI: 27.5 to 36.7), and stress (29.6%; 95% CI: 24.3 to 35.4) in the general 272 
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population during the COVID-19 pandemic (65). Collectively, these data suggest that during the 273 
current pandemic, women with PCOS are experiencing a greater psychological burden than the general 274 
population, with a markedly higher prevalence. This is in accord with the latest international evidence-275 
based guidance on PCOS, which highlights that, irrespective of a global pandemic, women with PCOS 276 
are more likely to experience depression and anxiety (66). 277 
Other reported risk factors for decreased sleep quality during the COVID-19 pandemic are changes to 278 
sleep patterns (61), worries about health (67), financial consequences (68), social interactions (69), 279 
reduced physical activity (62), and gender with women being reportedly 56% more likely than men to 280 
experience sleep disruption during this pandemic (70). As such, it is plausible that such factors further 281 
contribute to a potential multifactorial effect upon an already ‘at risk’ population (71), which clearly 282 
exacerbates sleep disruption and may result in reduced QoL. Indeed, the results of the present study 283 
support this notion, since women with PCOS who reported negative sleep effects during the COVID-284 
19 pandemic also exhibited reduced QoL (as measured by the PCOSQOL) compared to those without 285 
any, or with positive effects on sleep. Based on the corresponding PCOSQOL domains, this association 286 
was apparently burdened by the impact of PCOS and affected mood in the study participants. However, 287 
what cannot be determined by the present findings is the directional role of sleep disruption in the 288 
aforementioned milieu for which further studies are clearly needed. 289 
Interestingly, longitudinal studies have previously reported associations between sleep disorders, 290 
anxiety, and depression (72, 73), which are known to independently impair QoL (74). Moreover, it has 291 
been purported that there is a bidirectional relationship between sleep quality and mental wellbeing 292 
(75), with sleep quality independently predicting the prevalence of anxiety and/or depression, whilst 293 
anxiety and depression are also predictors for reduced sleep quality (42, 76). Due to the nature of our 294 
analysis, the current study is unable to determine the causal direction between sleep and mental 295 
wellbeing. However, it is likely that the COVID-19 pandemic has created an overarching environment 296 
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which further exacerbates this relationship with the net result being further impairments of mental 297 
health and sleep quality leading to reduced QoL. As prior to the COVID-19 pandemic, women with 298 
PCOS were already recognized as a patient population at an increased risk of anxiety/stress, depression, 299 
sleep disorders and impaired QoL (18, 19); the disrupting circumstances of this pandemic mean then 300 
that there should be a renewed and heightened focus from healthcare professionals to ensure that 301 
adequate support and treatment provision is available to reduce and, where possible, prevent further 302 
comorbidity and impaired QoL in these women (16).  303 
Study Limitations 304 
There are certain limitations which should be acknowledged in the present study. This study relied 305 
upon participant self-report which can lead to a degree of decreased clarity/accuracy in the provided 306 
answers, thus inevitably introducing a degree of information bias to the study findings. For example, 307 
it is known that individuals tend to over-report their height and under-report their weight (77), an effect 308 
which appears to be further exaggerated in individuals with overweight/obesity (78). This may lead to 309 
discrepancies in self-reported anthropometric data which, given the key role of metabolic health in 310 
PCOS severity/comorbidity (79) and sleep quality (26) may impact to some degree on the study 311 
findings. However, this methodology is frequently employed in studies of this nature, whilst validated 312 
instruments/questionnaires were utilized to capture key study data of interest. Another study limitation 313 
is the lack of comparative baseline data for the study cohort for a period prior to the COVID-19 314 
pandemic. The study survey questions asked about changes in sleep quality due to COVID-19 315 
restriction measures, but without validated baseline measurements, it is not possible to quantify the 316 
exact extent to which the corresponding outcomes have been affected. This issue could be addressed 317 
to some degree at a follow-up time point when current restrictions have been eased/lifted. To this aim, 318 
the relevant prospective follow-up of this study cohort has been planned. Furthermore, although the 319 
large sample size in the present study is a distinct strength, it is accompanied by some inherent 320 
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limitations. For instance, OLR yielded significant R2N for all variables, yet most were of little practical 321 
significance; thus, in interpreting these results, the potential fallacy of large sample sizes must be 322 
considered (80). Finally, as this is a cross-sectional study, the present findings cannot be used to infer 323 
conclusions regarding the temporal/causal relationship between the noted negative impact on sleep and 324 
reported levels of depression/stress. 325 
5 Conclusion 326 
The present study offers a novel insight regarding the self-reported sleep quality of women with PCOS 327 
during the COVID-19 pandemic lockdown, and how this is associated with QoL and depression, 328 
anxiety, and stress levels in this population. Based on our present findings, it is evident that the majority 329 
of UK women with PCOS in this study cohort feel that the applied measures imposed in response to 330 
the COVID-19 pandemic had a negative impact on the quality of their sleep, with high prevalence of 331 
insomnia. There is also evidence that those women with PCOS and impaired sleep have greater levels 332 
of psychological morbidity (e.g., depression/stress) and reduced QoL. Whilst it appears that the 333 
restrictive measures due to COVID-19 have increased this comorbidity burden in these women with 334 
PCOS, the exact magnitude of the impact of this global pandemic upon these parameters and the 335 
underlying temporal/causal relationship is less clear. Nevertheless, it has previously been reported that 336 
during such disease outbreaks, the number of individuals whose mental health is negatively affected 337 
can be greater than the number affected by the infection (81), and that the mental health implications 338 
and their prevalence can be even more significant than the epidemic itself (82). Another key message 339 
to consider based on the present study is that there are certain groups that may remain relatively 340 
overlooked despite being particularly vulnerable during this pandemic. Women with PCOS should be 341 
considered within these parameters, since they are at increased risk of cardio-metabolic complications 342 
which, in turn, may increase the risk of severe COVID-19, whilst they are also susceptible to significant 343 
psychological comorbidity which, regardless of COVID-19, may impair their overall wellbeing. 344 
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Table 1. Breakdown of socioeconomic and ethnicity characteristics of interest for the study cohort of UK women 578 
with polycystic ovary syndrome [PCOS; N = 333; median age (interquartile range) = 30.0 (9.0) years].  579 
Variable N (%) 
Ethnicity  
White 308 (92.5) 
Mixed background 9 (2.7) 
Asian or Asian British 8 (2.4) 
Black or Black British 4 (1.2) 
Other ethnic background 3 (0.9) 
Declined to indicate 1 (0.3) 
Relationship status  
Single 134 (40.2) 
Married 132 (39.6) 
Co-habiting 22 (6.6) 
Long-term relationship 19 (5.7) 
Civil-partnership  12 (3.6) 
Engaged 8 (2.4) 
Divorced 3 (0.9) 
Separated 2 (0.6) 
Widowed 1 (0.3) 
Children  
No 242 (72.7) 
Yes 91 (27.3) 
Education  
Undergraduate  135 (40.2) 
College 107 (32.1) 
Postgraduate  60 (18.0) 
Secondary 26 (7.8) 
Doctorate 5 (1.5) 
Employment  
Full-time employment 210 (63.1) 
Part-time employment 47 (14.1) 
Student 27 (8.1) 
House person 19 (5.7) 
Unemployed 21 (6.3) 
Self-employed 9 (2.7) 
Household income  
≤ £39,999 170 (51.1) 
£40,000-£79,999 137 (41.1) 
≥ £80,000 26 (7.8) 
All percentage data has been rounded to one decimal place. 
 580 
  
Table 2. Key outcomes of interest for the study cohort of UK women with polycystic ovary syndrome 581 
(PCOS) when split into a dichotomous response regarding the impact of the lockdown measures due 582 
to COVID-19 on sleep (reported negative effects versus no or positive effect).  583 
Study Variables/Outcomes 
Full study cohort of 
women with PCOS  
(N = 333) 
Negative impact 
on sleep  
(N = 242) 
No/Positive 
impact on sleep 
(N = 91) 
P 
Age (years) 30.0 (9.0) 29.0 (9.0) 30.0 (10.3) .426 
Years Since PCOS Diagnosis 8.0 (9.9) 7.3 (9.8) 8.2 (12.0) .336 
Weight (kg) 93.9 (37.9) 93.9 (37.2) 91.2 (37.5) .290 
BMI (kg/m2) 34.8 (13.6) 35.0 (13.1) 34.0 (14.7) .322 
PCOSQOL      
Total Score 101.0 (60.5) 97.0 (59.0) 114.0 (65.8) .003 
Impact of PCOS 40.0 (28.5) 38.0 (26.0) 50.5 (30.5) .001 
Infertility 24.0 (27.0) 23.0 (27.0) 30.5 (26.5) .077 
Hirsutism 16.0 (18.0) 16.0 (17.0) 17.5 (20.3) .348 
Mood 17.0 (10.0) 16.0 (9.0) 21.0 (11.0) .001 
DASS-21     
Depression 18.0 (17.0) 18.0 (16.0) 13.0 (16.0) .014 
Anxiety 10.0 (12.0) 12.0 (12.0) 10.0 (11.0) .094 
Stress 18.0 (14.0) 18.0 (12.0) 15.0 (14.5) .007 
Insomnia Severity 12.0 (9.5) 14.0 (8.0) 7.0 (8.0) <.001 
Comorbidities 1.0 (2.0) 1.0 (2.0) 1.0 (3.0) .737 
Data are presented as median (interquartile range). Between group comparisons performed by independent 
samples Mann-Whitney U tests. Insomnia severity as assessed by the validated Insomnia Severity Index (ISI). 
Significance was set at p<0.05. BMI: body mass index; PCOSQOL: Polycystic ovary syndrome quality of 





Table 3. Results from the ordinal logistic regression (OLR) for the study cohort of UK women with polycystic ovary syndrome (PCOS). 587 
  95% CI      95% CI       
Predictor β Lower Upper SE Z OR Lower Upper Wald χ² R²N p 
DASS-21 Stress 0.21 0.17 0.25 0.02 9.055 1.23 1.18 1.29 87.23 0.05 < .0001 
DASS-21 Anxiety 0.17 0.13 0.22 0.02 7.793 1.19 1.14 1.25 64.06 0.03 < .0001 
DASS-21 Depression 0.14 0.11 0.18 0.01 7.314 1.15 1.11 1.20 55.5 0.03 < .0001 
PCOSQOL Mood -0.12 -0.1 -0.08 0.01 -7.692 0.88 0.86 0.91 62.49 0.02 < .0001 
PCOSQOL Hirsutism -0.03 -0.05 -0.01 0.008 -3.288 0.97 0.95 0.99 10.98 0.005 .001 
PCOSQOL Infertility -0.03 -0.04 -0.01 0.006 -3.942 0.97 0.96 0.98 15.79 0.008 < .0001 
PCOSQOL Impact of PCOS -0.03 -0.04 -0.02 0.005 -6.771 0.96 0.95 0.97 48.01 0.02 < .0001 
CI: Confidence Interval, β: beta-coefficient, SE: Standard Error, OR: Odds ratio, R²N: Nagelkerke's pseudo-R² 
PCOSQOL: Polycystic ovary syndrome quality of life questionnaire; DASS-21: Depression, Anxiety and Stress Scale (21 item) 
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